Vironexis is focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV Gene Therapy Platform enables the creation of off-the-shelf, single-dose gene therapies designed to overcome the key challenges and shortcomings of current immunotherapies, including CAR-T. Our current pipeline includes more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is anticipated to begin clinical trials in the fourth quarter of 2024.
Company Details
- Employees
- 11
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://vironexis.com
- Keywords
- San Diego.
Vironexis Biotherapeutics Questions
Vironexis Biotherapeutics's website is http://vironexis.com
Vironexis Biotherapeutics's LinkedIn profile is https://www.linkedin.com/company/vironexis
Vironexis Biotherapeutics has
11 employees.
View email and phone details for 11
employees at Vironexis Biotherapeutics.
Vironexis Biotherapeutics's industry is
Biotechnology Research
Vironexis Biotherapeutics's top competitors are
Chai Discovery,
Nalu Medical, Inc.,
Superluminal Medicines Inc.,
858 Therapeutics,
Wildfire Systems, Inc,
Splitero,
Cardiatec Bio,
Radiant Biotherapeutics,
Safi Biotherapeutics Inc,
Firestorm.
Vironexis Biotherapeutics's categories are Biotechnology Research
Vironexis Biotherapeutics's founding year is 2021
